Abstract Background: Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody indicated for the treatment of inadequately controlled severe persistent asthma despite optimal controller therapy. It is an expensive medication so there is a need to identify those patients most likely to benefit.
Introduction
IgE is central to the pathophysiology of allergic asthma and related conditions such as allergic rhinitis, providing a strong rationale for the development of anti-IgE therapy for the treatment of these diseases [1] .
Omalizumab is a recombinant humanized monoclonal antibody IgG1 that selectively binds to human immunoglobulin E (IgE). It is constructed from the constant region of IgG1 k human framework with a variable sequence of mouse antibody. It is >95% human IgG and <5% mouse antibody [2] . By binding to free IgE, omalizumab reduces the level of circulating free IgE by up to 99%, prevents IgE from attaching to mast cells and basophiles, down-regulates FceRI expression, and attenuates the inflammatory response to allergens [3] . The current indication for omalizumab is the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum IgE levels corresponding to the recommended dose range (>30 to 700 IU/ml) [4] .
Treatment with omalizumab attenuates early and late phase responses to inhaled allergen challenge. There is accumulating evidence to show that omalizumab reduces the activity of a variety of pro-inflammatory cells (including eosinophils, mast cells and basophils) and down-regulates release of pro-inflammatory mediators, thereby attenuating both the acute and chronic phases of allergic inflammation. In addition, the effects of omalizumab on antigen-presenting cells (dendritic cells) indicate that it may also block the sensitization phase, as well as the effector phase [5] .
Clinical studies in patients with asthma have shown that omalizumab reduces asthma exacerbations, severe asthma exacerbations, inhaled corticosteroid requirements, and emergency visits, as well as significantly improving asthma-related quality of life, morning PEF and asthma symptom scores in patients with severe allergic (IgE-mediated) asthma in addition to considerable reduction in the need for maintenance OCS, especially in patients with severe asthma and whose asthma is inadequately controlled despite Global Initiative for Asthma (GINA) step 4 therapy, usually termed difficult-to-treat asthma.
Omalizumab is an expensive medication, the actual costs are relative to the dose required, but range from about AU$ 7800 to 50,000 per annum. Moreover, although the safety profile of omalizumab, as available from early controlled studies and post-marketing experience, appears favorable, the occurrence of anaphylactic reactions and concerns regarding the possibility of increased rates of malignancy should lead to cautionary measures in obtaining consent and managing subjects. Thus, in addition to strict criteria for selection, the most important of which are to confirm the diagnosis of asthma, to exclude masquerading conditions and to ensure that optimal conventional therapy has been tried, there is also a need to identify individual responders to this drug, rather than recommend widespread use in difficult asthma [1] [2] [3] [4] [5] .
The aim of the present exploratory analysis was to determine baseline patient characteristics that could be predictive of the best response to omalizumab therapy for allergic asthma.
Methods Study Patients
The study was prospective, open label, recruiting patients through the chest outpatient clinic in RCH, Jubail, KSA. The study enrolled patients with a diagnosis of severe persistent allergic asthma that was inadequately controlled (at least 6 months prior to enrolling in the study) despite step 4 treatment as described in the GINA 2002 guidelines [6] . Patients deemed eligible for omalizumab treatment have had their existing standard treatments optimized as well as having behavioral and psychosocial issues addressed 6 month before starting omalizumab.
Beginning in Jan 2009 till December 2011, we enrolled 42 patient with serum total IgE level of 30 to 700 IU/mL, and a had positive, immediate skin-prick test result to at least one common allergen (dust mite, dog or cat or cockroach).
The inclusion criteria for enrollment included adult and adolescent patients (12 years and older) with severe persistent allergic asthma who have a positive skin test to a perennial aeroallergen and who have reduced lung function (forced expiratory volume in 1 s, FEV1 < 80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta-2 agonist.
Exclusion criteria: (1) smoking status, (2) unconfirmed diagnosis of asthma, (3) comorbidities including COPD, chronic sinusitis, gastroesophageal reflux, obesity, obstructive sleep apnea, psychological and psychiatric disorders.
Study protocol
Baseline data was collected and included age, sex, duration of asthma, symptoms of asthma, daytime symptoms, limitation of activities, nocturnal symptoms/awakening, usage of rescue bronchodilators, lung function (FEV 1 ), bronchial reversibility, current asthma treatment, history of receiving OCS, skin-prick test result to common allergen, history of allergic rhinitis and/ or allergic dermatitis, sputum eosinophilia (P3%), and baseline total (IgE), in addition to number of asthma exacerbation within the year prior to enrolling in the study.
Omalizumab was given as add-on therapy to standard asthma therapy which included inhaled corticosteroids (ICS), longacting beta-2 agonists, short-acting beta-2 agonists, oral corticosteroids (OCS), leukotriene antagonists and where appropriate, theophylline. Omalizumab is available as a powder for reconstitution with solvent, administered subcutaneously every 2 or 4 weeks according to patients' pretreatment bodyweight and baseline IgE levels using a dosing table for at least 16 weeks. The population cohort was assessed at 16 weeks for response to omalizumab treatment.
Throughout the study, patients recorded symptoms of asthma, daytime symptoms, limitation of activities, nocturnal symptoms/awakening, usage of rescue bronchodilators in daily diary cards.
Each patient was assessed to establish his or her current treatment regimen, adherence to the current regimen, and level of asthma control during monthly clinic visits using GINA guidelines' simplified scheme for recognizing controlled, partly controlled, and uncontrolled asthma [6] . If control has been maintained for three months, treatment can be stepped down with the aim of establishing the lowest step and dose of treatment that maintains control. If asthma is partly controlled, an increase in treatment should be considered.
Outcome measures
Degree of asthma control; success in initiating oral corticosteroids withdrawal; or step down of high dose ICS; control of exacerbations; the number of clinically significant asthma exacerbations during the treatment phase, avoidance of unscheduled healthcare utilization; spirometry measures and a global evaluation of treatment effectiveness, as assessed by the physician. An exacerbation was defined as worsening of asthma symptoms severe enough to require systemic steroids or a doubling of the patients' baseline ICS dose [7] .
Identifying patients who respond to omalizumab therapy
Overall asthma control [6] is especially relevant in severe asthma as it takes into account many aspects of clinical disease.
Those who showed improvement in degree of asthma control using GINA guidelines' scheme [6] were labeled as Good Responders to omalizumab, with assessment of success in initiating oral corticosteroids withdrawal; success in step down of high dose ICS; or other asthma treatment, less need of rescue medication, less daytime symptoms, less nocturnal symptoms, better control of exacerbations, less ER visits, improvement in FEV1 and physician's overall assessment.
Statistical analysis

Data entry and analysis
After the data were collected, they were coded and transferred directly into the computer. The Statistical Package for Social Science (SPSS) was used. The following descriptive measures were used: count, percent, arithmetic mean and standard deviation. Correlation matrix was done to study the relation between two or more quantitative variables. The least significant level was at P < 0.05.
Ability of pre-treatment baseline measures to predict response to omalizumab
Univariate and multivariate analysis were performed where the response to omalizumab was the dependent variable and the following baseline variables were included in the model as independent variables: age, sex, duration of asthma, degree of asthma control, lung function (FEV 1 ), bronchial reversibility, history of receiving OCS, no of positive results in skinprick test to common allergen, history of allergic rhinitis, allergic dermatitis, sputum eosinophilia, and baseline total (IgE), in addition to number of asthma exacerbation within the year prior to enrolling in the study.
Results
Patient population comprised 42 adults (15 female, 27 male), with age range (20 y-52 y), with severe asthma that was inadequately controlled despite step 4 treatment as described in (GINA) guidelines and who were eligible for omalizumab treatment for at least 16 weeks.
Baseline characteristics of patient population are showed in (Table 1) ; Patient had asthma duration range from {14-32 with (mean ± SD) 20.0 ± 5.0}. 9.5% of patient had prednisone-dependent asthma; 66.6% had concomitant allergic rhinitis, 11.9% had concomitant allergic dermatitis; and 14.3% showed sputum eosinophilia (P3%). Baseline IgE range from {80À730 (mean ± SD) 500 ± 83} IU/mL; base line usage of rescue bronchodilators (puff/day) showed mean of 5.2 ± 3.0, baseline bronchial reversibility range from {(12-25%) (mean ± SD) 18 ± 4.8} and baseline FEV 1 range from {44-75 (mean ± SD) 62.7 ± 10.8}.
Identifying patients who respond to omalizumab therapy
Before starting omalizumab, 25 patient out of 42 (59.5%) were in the category of uncontrolled asthma and 17/42 (40.5%) were in the category of partly controlled asthma, no one in our cohort was in the controlled category. Based on definition of response, as improvement in degree of asthma control according to GINA guidelines (Table 2) , with no asthma exacerbation during 16 weeks of treatment, 12 patients of our cohort (28.6%) showed response omalizumab and were labeled as responders (Table 3) .
On comparing baseline characteristics of patients in omalizumab responder and non-responder groups, there was no statistical significant difference in gender, usage of rescue bronchodilators, FEV 1 ,%, history of receiving OCS, and number of asthma exacerbation within the year prior to enrolling in the study. Responder group showed significantly higher bronchial reversibility, higher baseline IgE, and higher no. of positive allergens. Also responder group showed higher rates of allergic rhinitis, allergic dermatitis, and sputum eosinophilia. Responder group had Less duration of asthma, and younger age (Table 4) .
Correlation coefficients between baseline characteristics of patients and response to omalizumab is shown in (Table 5) .
In the univariate analysis, age, duration of asthma, history of allergic Rhinitis, history of allergic dermatitis, bronchial reversibility, no of positive results to common allergen in immediate skin-prick, sputum eosinophilia and baseline total (IgE) had an interaction with response to omalizumab, with predictive value of improvement in asthma control, whereas inconsistent results were obtained for gender, usage of rescue bronchodilators, FEV 1 ,%, history of receiving OCS, and num-ber of asthma exacerbation within the year prior to enrolling in the study.
Using the multivariate regression analysis, a significant effect of allergic rhinitis, sputum eosinophilia and no of positive allergens on treatment response was consistent (95% [CI], 0.25 to 0.38; p < 0.000), (95% CI, 0.13 to 0.15; p < 0.000), and (95% CI, 0.12 to 0.09), respectively (Table 6) . 
Discussion
Omalizumab is an expensive medication and, it is important to recognize that not all patients respond to omalizumab treatment. Identification of those patients most likely to achieve the greatest benefit from omalizumab therapy will minimize unwarranted drug exposure and healthcare expenditure. Omalizumab treatment should only be initiated after a comprehensive and exhaustive assessment including establishment of correct diagnosis and compliance with standard optimized treatments especially ICS [8] .
It is recommended that the physician's overall assessment should be used to identify responders after 16 weeks of therapy, thus targeting the treatment to the patients most likely to benefit. When treatment is directed at these responders, omalizumab has been shown to provide cost effective therapy for inadequately controlled severe persistent allergic (IgE-mediated) asthma [1] .
Predicting response to omalizumab in patients with inadequately controlled severe persistent allergic asthma is of great clinical relevance. Careful clinical assessment of response is required using validated tools. In the present study, based on GINA guidelines, we used the improvement in degree of asthma control as indicator of response to omalizumab and to characterize baseline features of such patients. Overall, on the basis of extensive clinical information available, it appears that the greatest benefit from add-on omalizumab therapy is observed for the subgroup of more difficult-to-treat patients [9] .
In the present study, it is worth noting that, 12 patients of our cohort showed response to omalizumab (Response rate 28.6%). We defined response by strict criteria of GINA guidelines, which is the improvement in degree of asthma control with no asthma exacerbation during 16 weeks of treatment. Before starting omalizumab, all our patients were considered to have severe asthma as 25 patient out of 42 (59.5%) were in the category of uncontrolled asthma and 17/42 (40.5%) were in the category of partly controlled asthma, despite optimized treatment for at least 6m before commencing the study.
In this respect, Bousquet et al. [9] have analyzed data from several trials to examine predictors of response to omalizumab as add on therapy in severe asthma. They found that the response rate was 65% at 16 weeks and a minimum trial of 12 weeks was recommended. Response rate in the current study is much less (28.6%). This difference is mostly because we used more strict measure of response, that is improvement in degree of control of asthma as defined by GINA guidelines. Whereas, Bousquet et al. [9] defined response by a composite measure of one of four criteria with no asthma exacerbation over 16 weeks therapy; these criteria are; reduced symptoms P1 mean total asthma score with no increase in beta 2 agonist use; reduction P1 mean number of puffs rescue medication/day with no increase in total symptom score; mean increase in PEF P15%; increase overall score P1 Juniper Asthma QOL questionnaire.
In a subsequent large study by Bousquet et al. [7] , physician's overall assessment of treatment was found to be the most reliable tool to identify patients who respond to omalizumab and no one item appearing more reliable than global assessment. They concluded that this simple measurement can be used to determine whether treatment should continue beyond an initial 16-week trial of omalizumab therapy. Importantly, lung function improvement only identified approximately half of those who ''responded'' to omalizumab. These data strengthen our choice of improvement in degree of control of asthma defined by GINA guidelines as a measure of response to omalizumab.
The predictors of response in Bousquet et al. [9] study, included a history of ED treatment in the last 12 months, high dose of inhaled BDP and low FEV1, while in our study responder group showed significantly higher bronchial reversibility, higher baseline IgE, and higher no. of positive allergens in skin prick test. Also responder group showed higher rates of allergic rhinitis, allergic dermatitis, and sputum eosinophilia and had less duration of asthma, and younger age.
Bousquet and colleagues [10] , presented large study with pooled data from seven studies; five blinded placebo-controlled plus inhaled corticosteroid, and two open label against current asthma treatment. The studies attempted to identify a group of patients in whom the efficacy of omalizumab was most clearly established by observing exacerbation rates in subgroups of the pooled dataset. They reported that most of the patients were in the severe persistent category of asthma severity by GINA guidelines and overall, the hospital admissions were reduced by 52%, emergency room visits by 61%, unscheduled doctor visits by 47% and a 47% reduction in exacerbations for the omalizumab group. But they reported that it is difficult to predict which patients will gain most benefit from treatment with omalizumab based on pre -treatment baseline characteristics as none of the studied variables (age, sex, FEV 1 and IgE levels) could predict those who responded to omalizumab.
In contrary to Bousquet et al. study, we observed in our analysis that age, duration of asthma, history of allergic rhinitis, history of allergic dermatitis, bronchial reversibility, no of positive results to common allergen in immediate skin-prick, sputum eosinophilia and baseline total (IgE) had an interaction with response to omalizumab, with predictive value of improvement in asthma control. On the other hand, other variables did not show correlation with response to omalizumab including gender, usage of rescue bronchodilators, FEV 1 %, history of receiving OCS, and number of asthma exacerbation within the year prior to enrolling in the study, Using the multivariate regression analysis, a significant effect of allergic rhinitis, sputum eosinophilia and no of positive allergens were found to be consistent predictor of treatment response (95% [CI], 0.25 to 0.38; p < 0.000), (95% CI, 0.13 to 0.15; p < 0.000), and (95% CI, 0.12 to 0.09), respectively.
In this respect, our observations have been confirmed by many studies. In the INNOVATE study [8] , baseline total IgE was the only consistent predictor of response to emerge from the univariate and multivariate analyses. However, pooled analysis of baseline total IgE levels across clinically important response measures did not consistently support this.
Allergic asthma and allergic rhinitis frequently co-exist, and are often considered to be components of a single IgE-mediated inflammatory condition [11] . Several trials of omalizumab have been conducted in patients with allergic rhinitis [12] . SO-LAR study [13] , evaluated omalizumab in patients with concomitant asthma and perennial allergic rhinitis (PAR), and showed that in addition to reducing asthma exacerbations, omalizumab also improved asthma and rhinitis scores on quality of life scales and led to significant improvements in rhinitis symptoms. Same results were found in other two studies in patients with seasonal allergic rhinitis (SAR) [14] and one in patients with (PAR) [15] . In all three studies, omalizumab significantly reduced symptom severity and rescue antihistamine use, as well as significantly improving rhinitis or rhinoconjunctivitis-related quality of life in SAR.
In the same context, several small studies and case reports have been published which indicate a potential benefit of omalizumab therapy in patients with urticaria. In one small study in patients with chronic autoimmune urticaria, 12 to 16 weeks following initiation of omalizumab, Urticaria Activity Score and rescue medication use were significantly decreased, and quality of life was improved [1] .
The above studies and our results suggest that omalizumab may provide additional benefit to omalizumab-treated asthma patients who also suffer with allergic rhinitis and/or allergic dermatitis. This may indicate that the more the atopic state the more the possibility of good response to omalizumab.
Omalizumab has been shown to bring about substantial reductions in the activity of IgE, eosinophils, basophils, mast cells, and dendritic cells, resulting in attenuation of the acute and chronic effector phases of allergic inflammation. [5] A pooled analysis found that omalizumab reduced mean peripheral blood eosinophil counts, in patients with moderate to-severe persistent asthma [14, 16] . Omalizumab has also been shown to reduce sputum and bronchial eosinophilia in a study of 45 patients with mild-to-moderate persistent asthma and persistent airway inflammation [17] . At 16 weeks, reductions in mean percentage sputum eosinophil counts were significantly greater in omalizumab-treated patients (from 4.8% at baseline to 0.6% at Week 16) than in placebo recipients (from 5.8% to 2.3%). Eosinophil counts in the bronchial submucosa also decreased from80 cells/mm2 at baseline to 1.5 cells/mm2 at Week 16 in the omalizumab group, but were almost unchanged in the placebo group.
These findings have been confirmed in a study in 25 patients with mild allergic asthma [18] . The median sputum percentage eosinophil count was reduced from 4.0% at baseline to 0.5% at 12 weeks in omalizumab-treated patients, compared with an increase from 2.2% to 2.6% in the placebo group. There was also a significant reduction in median activated eosinophil counts in biopsies in the omalizumab group (from 15.0 to 0.2 cells/0.1 mm 2 ), with little change in the placebo group)from 14.5 to 11.0 cells/0.1 mm 2 . Additionally, omalizumab-treated patients had significant reductions in submucosal IgE+ cells, and CD4+ T-lymphocytes. Taken together, these findings indicate that reductions in asthma exacerbations brought about by omalizumab may be mediated through attenuation of airway eosinophilia, while the reductions in IL-4+ cells may be important in light of the documented association between persistent IL-4 production and severe or corticosteroid-resistant asthma [19] . Moreover all the above data can explain our finding of correlation between sputum eosinophilia and response to omalizumab and support the role of sputum eosinophilia as predictor of omalizumab response.
Although history of receiving OCS did not show correlation with response to omalizumab, effect of omalizumab on need for systemic corticosteroid treatment has been confirmed in many studies. Busse and co-workers [20] have studied the effect of omalizumab on the need for rescue treatment with corticosteroids. The rate of courses of systemic corticosteroids was reduced in omalizumab-treated patients relative to control with an OR of 0.57 (0.48-0.66). This reduction closely correlated with both physician and patient global assessments. Treatment with omalizumab allowed a significant reduction in concomitant ICS dosage and had oral steroid-sparing benefits for patients [4] .
IgE continues to contribute to disease pathogenesis in atopic subjects who have persistent asthma despite treatment with ICS. In-vitro studies [21] show that corticosteroids enhance, rather than diminish, IgE production by a direct action on B cells. Thus, while having the ability to suppress T-helper type 2 cytokine production, a downside of repeated high-dose ICS treatment could be the maintenance of an ongoing local IgE response that could be amenable to omalizumab therapy. We understood that omalizumab can provide steroid-sparing benefits for patients on oral steroids but small no of patients on oral steroids in our study did not allow to investigate this theory.
We found that factors indicating more severe asthma including FEV 1 %, usage of rescue bronchodilators, and number of asthma exacerbation within the year prior to enrolling in the study were not correlated with response to omalizumab, this raise the probability that the response to omalizumab was relatively independent of disease severity.
Also the negative correlation of both duration of asthma and age with the response to omalizumab indicate that omalizumab may be less effective in severe chronic stages of asthma with well established irreversible changes of airways remodeling, so it may be wise to start omalizumab early, however this theory need to be confirmed by more studies.
Conclusion
As highlighted above, the present study showed that it is possible to reliably predict which patients will derive the greatest benefit from omalizumab therapy based on pre-treatment baseline characteristics. Overall, Asthma patients who benefit most from add-on treatment with omalizumab are those with shorter duration of asthma, younger age, history of allergic rhinitis or allergic dermatitis, more positive results to common allergen in immediate skin-prick, sputum eosinophilia, bronchial reversibility or higher baseline total (IgE). A potential criticism of our study, is the small number of our cohort but the fact that the results are so consistent and hang together clinically as well as statistically, encourages us to believe that they are reliable and replicable. Taken together, these findings will aid the clinical decision of whether a patient is likely to benefit from receiving omalizumab in addition to standard therapy for allergic asthma. Ongoing studies continue to evaluate the treatment benefits of omalizumab and guide therapy. Further studies are needed to investigate the potential predictive value of other biomarkers including baseline levels of specific IgE, the potential for disease-modification in asthma by use of omalizumab, as is the use of omalizumab in other IgE-mediated conditions.
